Adenoviral overexpression of apolipoprotein A-V reduces serum levels of triglycerides and cholesterol in mice

被引:177
作者
van der Vliet, HN
Schaap, FG
Levels, JHM
Ottenhoff, R
Looije, N
Wesseling, JG
Groen, AK
Chamuleau, RAFM
机构
[1] AMC Liver Ctr, NL-1105 BK Amsterdam, Netherlands
[2] Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, NL-1105 AZ Amsterdam, Netherlands
关键词
adenoviral vector; apolipoprotein; atherosclerosis; cholesterol metabolism; lipid homeostasis; triglyceride metabolism;
D O I
10.1016/S0006-291X(02)00808-2
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Mice lacking ApoA-V, a novel HDL-associated apolipoprotein identified by our group and independently by Permacchio et al. [Science 294 (2001) 169], were recently shown to be hypertriglyceridemic. To study the role of ApoA-V in triglyceride homeostasis, we compared lipid profiles in mice expressing normal and highly elevated levels of ApoA-V. For this purpose, adenoviral vectors expressing sense or antisense ApoA-V cDNA were constructed. Treatment of mice with sense adenoviral constructs resulted in circa 20-fold higher serum ApoA-V levels compared with mice injected with either PBS or antisense adenoviral constructs. ApoA-V overexpressing mice had markedly decreased (-70%) serum triglyceride levels caused primarily by lowered triglyceride content of the VLDL fraction. Furthermore, in these mice cholesterol levels were found to be lowered in all lipoprotein fractions with the largest mass decrease in the HDL fraction. This resulted in a 40% drop of serum cholesterol content. These findings suggest a role of ApoA-V in regulating levels of circulating triglycerides and cholesterol. (C) 2002 Elsevier Science (USA). All rights reserved.
引用
收藏
页码:1156 / 1159
页数:4
相关论文
共 11 条
[1]   ATHEROGENIC LIPOPROTEIN PHENOTYPE - A PROPOSED GENETIC-MARKER FOR CORONARY HEART-DISEASE RISK [J].
AUSTIN, MA ;
KING, MC ;
VRANIZAN, KM ;
KRAUSS, RM .
CIRCULATION, 1990, 82 (02) :495-506
[2]  
BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911
[3]   HYPERTRIGLYCERIDEMIA ASSOCIATED WITH DEFICIENCY OF APOLIPOPROTEIN-C-II [J].
BRECKENRIDGE, WC ;
LITTLE, JA ;
STEINER, G ;
CHOW, A ;
POAPST, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1978, 298 (23) :1265-1273
[4]   Mouse models of atherosclerosis [J].
Breslow, JL .
SCIENCE, 1996, 272 (5262) :685-688
[5]   Triglycerides and coronary risk [J].
Gaziano J.M. .
Current Cardiology Reports, 1999, 1 (2) :125-130
[6]  
Hardardottir Ingibjorg, 1994, Current Opinion in Lipidology, V5, P207, DOI 10.1097/00041433-199405030-00008
[7]   A simplified system for generating recombinant adenoviruses [J].
He, TC ;
Zhou, SB ;
da Costa, LT ;
Yu, J ;
Kinzler, KW ;
Vogelstein, B .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (05) :2509-2514
[8]   Distribution and kinetics of lipoprotein-bound endotoxin [J].
Levels, JHM ;
Abraham, PR ;
van den Ende, A ;
van Deventer, SJH .
INFECTION AND IMMUNITY, 2001, 69 (05) :2821-2828
[9]   An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing [J].
Pennacchio, LA ;
Olivier, M ;
Hubacek, JA ;
Cohen, JC ;
Cox, DR ;
Fruchart, JC ;
Krauss, RM ;
Rubin, EM .
SCIENCE, 2001, 294 (5540) :169-173
[10]   Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism [J].
Shachter, NS .
CURRENT OPINION IN LIPIDOLOGY, 2001, 12 (03) :297-304